Hematologic Malignancies at the Cutting Edge of Immunotherapy, Expert Says – Targeted Oncology
|
Hematologic Malignancies at the Cutting Edge of Immunotherapy, Expert Says
Targeted Oncology “I think that we have always been ahead of the curve—as far as moving new treatments forward—and with respect to immunotherapy, we are also at the cutting edge,” said Leonard, a professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian … |
|
uniQure (QURE) Presents Data on Successful Readministration of Gene Therapy in Non-Human Primates
StreetInsider.com uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented data on successful repeated hepatic gene delivery with uniQure’s AAV5 vector following a … |